BACKGROUND:Medical pretreatment before pulmonary endarterectomy (PEA) can optimize right ventricular (RV) function and may improve postoperative outcome in high-risk patients. Using cardiac magnetic resonance imaging (cMRI), we determined whether the dual endothelin-1 antagonist bosentan improves RV function and remodeling in patients with chronic thromboembolic pulmonary hypertension (CTEPH) who waited for PEA. HYPOTHESIS: We hypothesized that medical therapy prior to PEA will be associated with improvements in RV remodeling and function. METHODS: In this pilot study, 15 operable CTEPH patients were randomly assigned to either bosentan (n = 8) or no bosentan (n = 7, control) for 16 weeks, next to "best standard of care." Both before and after treatment, RV stroke volume index (RVSVI), RV ejection fraction (RVEF), RV mass, RV isovolumic relaxation time (rIVRT), leftward ventricular septal bowing (LVSB), and left ventricular ejection fraction (LVEF) were determined using cMRI. RESULTS: After 16 weeks, the change (Δ) from baseline (median [range]) in the studied cMRI parameters differed significantly between the bosentan group and the controls: Δ RVSVI: 6 [-4-11] vs 1 [-6-3] mL/m(-2) ; Δ RVEF: 8 [-10-15] vs -4 [-7-5]%; Δ RV mass: -3 [-6--2] vs 2 [-1-3] g/m(-2) ; Δ rIVRT: -30 [-130-20] vs 10 [-30-30] msec; Δ LVSB: 0.03 [-0.03-0.13] vs -0.03[-0.08-0.04] cm(-1) ; and Δ LVEF: 8 [-5-17] vs -2 [-14-2]% (all P < 0.05). The change from baseline in mean pulmonary artery pressure (-11 [-17-11] vs 5 [-6-21] mm Hg, P < 0.05) and 6-minute walk distance (20 [3-88] vs -4 [-40-40] m, P < 0.05) also differed significantly. CONCLUSIONS: In CTEPH, compared with control, treatment with bosentan for 16 weeks was associated with a significant improvement in cMRI parameters of RV function and remodelling.
RCT Entities:
BACKGROUND: Medical pretreatment before pulmonary endarterectomy (PEA) can optimize right ventricular (RV) function and may improve postoperative outcome in high-risk patients. Using cardiac magnetic resonance imaging (cMRI), we determined whether the dual endothelin-1 antagonist bosentan improves RV function and remodeling in patients with chronic thromboembolic pulmonary hypertension (CTEPH) who waited for PEA. HYPOTHESIS: We hypothesized that medical therapy prior to PEA will be associated with improvements in RV remodeling and function. METHODS: In this pilot study, 15 operable CTEPHpatients were randomly assigned to either bosentan (n = 8) or no bosentan (n = 7, control) for 16 weeks, next to "best standard of care." Both before and after treatment, RV stroke volume index (RVSVI), RV ejection fraction (RVEF), RV mass, RV isovolumic relaxation time (rIVRT), leftward ventricular septal bowing (LVSB), and left ventricular ejection fraction (LVEF) were determined using cMRI. RESULTS: After 16 weeks, the change (Δ) from baseline (median [range]) in the studied cMRI parameters differed significantly between the bosentan group and the controls: Δ RVSVI: 6 [-4-11] vs 1 [-6-3] mL/m(-2) ; Δ RVEF: 8 [-10-15] vs -4 [-7-5]%; Δ RV mass: -3 [-6--2] vs 2 [-1-3] g/m(-2) ; Δ rIVRT: -30 [-130-20] vs 10 [-30-30] msec; Δ LVSB: 0.03 [-0.03-0.13] vs -0.03[-0.08-0.04] cm(-1) ; and Δ LVEF: 8 [-5-17] vs -2 [-14-2]% (all P < 0.05). The change from baseline in mean pulmonary artery pressure (-11 [-17-11] vs 5 [-6-21] mm Hg, P < 0.05) and 6-minute walk distance (20 [3-88] vs -4 [-40-40] m, P < 0.05) also differed significantly. CONCLUSIONS: In CTEPH, compared with control, treatment with bosentan for 16 weeks was associated with a significant improvement in cMRI parameters of RV function and remodelling.
Authors: Hossein A Ghofrani; Ralph T Schermuly; Frank Rose; Ralph Wiedemann; Markus G Kohstall; André Kreckel; Horst Olschewski; Norbert Weissmann; Beate Enke; Stefanie Ghofrani; Werner Seeger; Friedrich Grimminger Journal: Am J Respir Crit Care Med Date: 2003-01-24 Impact factor: 21.405
Authors: C Tji-Joong Gan; Jan-Willem Lankhaar; J Tim Marcus; Nico Westerhof; Koen M Marques; Jean G F Bronzwaer; Anco Boonstra; Pieter E Postmus; Anton Vonk-Noordegraaf Journal: Am J Physiol Heart Circ Physiol Date: 2005-11-11 Impact factor: 4.733
Authors: R J Hughes; X Jais; D Bonderman; J Suntharalingam; M Humbert; I Lang; G Simonneau; J Pepke-Zaba Journal: Eur Respir J Date: 2006-04-12 Impact factor: 16.671
Authors: P Bresser; P F Fedullo; W R Auger; R N Channick; I M Robbins; K M Kerr; S W Jamieson; L J Rubin Journal: Eur Respir J Date: 2004-04 Impact factor: 16.671
Authors: Stuart W Jamieson; David P Kapelanski; Naohide Sakakibara; Gerard R Manecke; Patricia A Thistlethwaite; Kim M Kerr; Richard N Channick; Peter F Fedullo; William R Auger Journal: Ann Thorac Surg Date: 2003-11 Impact factor: 4.330
Authors: Vittorio Pengo; Anthonie W A Lensing; Martin H Prins; Antonio Marchiori; Bruce L Davidson; Francesca Tiozzo; Paolo Albanese; Alessandra Biasiolo; Cinzia Pegoraro; Sabino Iliceto; Paolo Prandoni Journal: N Engl J Med Date: 2004-05-27 Impact factor: 91.245
Authors: Kelley L Colvin; Melanie J Dufva; Ryan P Delaney; D Dunbar Ivy; Kurt R Stenmark; Michael E Yeager Journal: Front Pediatr Date: 2014-02-03 Impact factor: 3.418